JP6111194B2 - 組み合わせ薬物送達方法および装置 - Google Patents

組み合わせ薬物送達方法および装置 Download PDF

Info

Publication number: JP6111194B2
Authority: JP; Japan
Prior art keywords: therapeutic agent; therapeutic; chamber; release; reservoir
Prior art date: 2010-08-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2013523372A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013538082A5 (zh

JP2013538082A (ja

Inventor

ユージーン・デ・フアン

ヤイル・アルスター

キャスリーン・コーガン・ファリナス

キャリー・ジェイ・ライク

ランドルフ・イー・キャンベル

ケイ・アンジェラ・マクファーラン

シーニェ・エリクソン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ForSight Vision4 Inc

Original Assignee

ForSight Vision4 Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-05

Filing date

2011-08-05

Publication date

2017-04-05

2011-08-05 Application filed by ForSight Vision4 Inc filed Critical ForSight Vision4 Inc

2013-10-10 Publication of JP2013538082A publication Critical patent/JP2013538082A/ja

2014-09-25 Publication of JP2013538082A5 publication Critical patent/JP2013538082A5/ja

2017-04-05 Application granted granted Critical

2017-04-05 Publication of JP6111194B2 publication Critical patent/JP6111194B2/ja

Status Active legal-status Critical Current

2031-08-05 Anticipated expiration legal-status Critical

Links

238000000034 method Methods 0.000 title description 24
238000012377 drug delivery Methods 0.000 title description 16
229940000425 combination drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 claims description 627
229940124597 therapeutic agent Drugs 0.000 claims description 561
230000001225 therapeutic effect Effects 0.000 claims description 327
210000004127 vitreous body Anatomy 0.000 claims description 130
238000002347 injection Methods 0.000 claims description 122
239000007924 injection Substances 0.000 claims description 122
210000003786 sclera Anatomy 0.000 claims description 65
230000004888 barrier function Effects 0.000 claims description 41
239000002525 vasculotropin inhibitor Substances 0.000 claims description 21
229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
239000002260 anti-inflammatory agent Substances 0.000 claims description 12
239000002246 antineoplastic agent Substances 0.000 claims description 12
238000002513 implantation Methods 0.000 claims description 12
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
238000000605 extraction Methods 0.000 claims 1
229940076783 lucentis Drugs 0.000 description 152
108091006146 Channels Proteins 0.000 description 145
210000001508 eye Anatomy 0.000 description 126
239000000203 mixture Substances 0.000 description 110
238000009472 formulation Methods 0.000 description 109
238000001802 infusion Methods 0.000 description 89
229960003876 ranibizumab Drugs 0.000 description 85
229940079593 drug Drugs 0.000 description 64
239000000463 material Substances 0.000 description 64
238000012360 testing method Methods 0.000 description 53
239000000243 solution Substances 0.000 description 45
238000013268 sustained release Methods 0.000 description 44
239000003112 inhibitor Substances 0.000 description 43
239000012730 sustained-release form Substances 0.000 description 42
230000000875 corresponding effect Effects 0.000 description 39
230000001186 cumulative effect Effects 0.000 description 39
229940120638 avastin Drugs 0.000 description 37
230000002401 inhibitory effect Effects 0.000 description 32
-1 for example Proteins 0.000 description 30
206010064930 age-related macular degeneration Diseases 0.000 description 29
239000002953 phosphate buffered saline Substances 0.000 description 28
238000011282 treatment Methods 0.000 description 28
238000004364 calculation method Methods 0.000 description 27
239000012530 fluid Substances 0.000 description 25
239000002245 particle Substances 0.000 description 23
239000011148 porous material Substances 0.000 description 23
150000003384 small molecules Chemical class 0.000 description 23
239000007787 solid Substances 0.000 description 23
YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 23
210000000795 conjunctiva Anatomy 0.000 description 22
239000000725 suspension Substances 0.000 description 22
208000005590 Choroidal Neovascularization Diseases 0.000 description 21
206010060823 Choroidal neovascularisation Diseases 0.000 description 21
239000012528 membrane Substances 0.000 description 21
229960002117 triamcinolone acetonide Drugs 0.000 description 21
239000007788 liquid Substances 0.000 description 20
229910052751 metal Inorganic materials 0.000 description 20
239000002184 metal Substances 0.000 description 20
210000001525 retina Anatomy 0.000 description 20
238000009792 diffusion process Methods 0.000 description 19
238000005259 measurement Methods 0.000 description 19
239000010935 stainless steel Substances 0.000 description 19
229910001220 stainless steel Inorganic materials 0.000 description 19
239000010936 titanium Substances 0.000 description 19
229910052719 titanium Inorganic materials 0.000 description 19
229940124638 COX inhibitor Drugs 0.000 description 18
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 18
229960000590 celecoxib Drugs 0.000 description 18
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 18
238000002474 experimental method Methods 0.000 description 18
238000004088 simulation Methods 0.000 description 17
239000003795 chemical substances by application Substances 0.000 description 16
238000011049 filling Methods 0.000 description 16
241000282414 Homo sapiens Species 0.000 description 15
238000003780 insertion Methods 0.000 description 15
230000037431 insertion Effects 0.000 description 15
239000004480 active ingredient Substances 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 13
229910000619 316 stainless steel Inorganic materials 0.000 description 12
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
230000008901 benefit Effects 0.000 description 12
150000001875 compounds Chemical class 0.000 description 12
230000007423 decrease Effects 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
239000011230 binding agent Substances 0.000 description 11
230000001886 ciliary effect Effects 0.000 description 11
201000010099 disease Diseases 0.000 description 11
230000004438 eyesight Effects 0.000 description 11
230000014759 maintenance of location Effects 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
241000282693 Cercopithecidae Species 0.000 description 10
108010050904 Interferons Proteins 0.000 description 10
102000014150 Interferons Human genes 0.000 description 10
230000000694 effects Effects 0.000 description 10
239000011521 glass Substances 0.000 description 10
230000028709 inflammatory response Effects 0.000 description 10
229940079322 interferon Drugs 0.000 description 10
230000003204 osmotic effect Effects 0.000 description 10
102000003820 Lipoxygenases Human genes 0.000 description 9
108090000128 Lipoxygenases Proteins 0.000 description 9
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 9
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 9
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 9
239000007789 gas Substances 0.000 description 9
239000000843 powder Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
206010061218 Inflammation Diseases 0.000 description 8
239000006260 foam Substances 0.000 description 8
239000000017 hydrogel Substances 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
239000002090 nanochannel Substances 0.000 description 8
229920000642 polymer Polymers 0.000 description 8
229920001296 polysiloxane Polymers 0.000 description 8
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 8
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 8
229960002930 sirolimus Drugs 0.000 description 8
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 8
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
230000033115 angiogenesis Effects 0.000 description 7
239000000739 antihistaminic agent Substances 0.000 description 7
230000009286 beneficial effect Effects 0.000 description 7
239000003966 growth inhibitor Substances 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
229960004752 ketorolac Drugs 0.000 description 7
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 7
238000001000 micrograph Methods 0.000 description 7
229960005294 triamcinolone Drugs 0.000 description 7
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 7
102000003390 tumor necrosis factor Human genes 0.000 description 7
230000006444 vascular growth Effects 0.000 description 7
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000001387 anti-histamine Effects 0.000 description 6
229940034982 antineoplastic agent Drugs 0.000 description 6
229960000397 bevacizumab Drugs 0.000 description 6
230000008859 change Effects 0.000 description 6
239000003246 corticosteroid Substances 0.000 description 6
230000009368 gene silencing by RNA Effects 0.000 description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
230000007774 longterm Effects 0.000 description 6
229920002521 macromolecule Polymers 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
208000031481 Pathologic Constriction Diseases 0.000 description 5
208000000208 Wet Macular Degeneration Diseases 0.000 description 5
229940022663 acetate Drugs 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000000919 ceramic Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
239000002086 nanomaterial Substances 0.000 description 5
239000004033 plastic Substances 0.000 description 5
229920003023 plastic Polymers 0.000 description 5
229920000515 polycarbonate Polymers 0.000 description 5
239000004417 polycarbonate Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000036262 stenosis Effects 0.000 description 5
208000037804 stenosis Diseases 0.000 description 5
210000002435 tendon Anatomy 0.000 description 5
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 4
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 4
102100035846 Pigment epithelium-derived factor Human genes 0.000 description 4
102000003923 Protein Kinase C Human genes 0.000 description 4
108090000315 Protein Kinase C Proteins 0.000 description 4
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
206010038848 Retinal detachment Diseases 0.000 description 4
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 4
108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 4
210000003161 choroid Anatomy 0.000 description 4
239000002131 composite material Substances 0.000 description 4
210000004087 cornea Anatomy 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
229940111134 coxibs Drugs 0.000 description 4
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
238000013016 damping Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
229960001259 diclofenac Drugs 0.000 description 4
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000013265 extended release Methods 0.000 description 4
229960002390 flurbiprofen Drugs 0.000 description 4
SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
229960005280 isotretinoin Drugs 0.000 description 4
230000003902 lesion Effects 0.000 description 4
238000011068 loading method Methods 0.000 description 4
208000002780 macular degeneration Diseases 0.000 description 4
229960003407 pegaptanib Drugs 0.000 description 4
108090000102 pigment epithelium-derived factor Proteins 0.000 description 4
230000004264 retinal detachment Effects 0.000 description 4
229960000371 rofecoxib Drugs 0.000 description 4
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
229940126586 small molecule drug Drugs 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
230000008685 targeting Effects 0.000 description 4
DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 3
MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
102100021866 Hepatocyte growth factor Human genes 0.000 description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
102000000521 Immunophilins Human genes 0.000 description 3
108010016648 Immunophilins Proteins 0.000 description 3
102100022337 Integrin alpha-V Human genes 0.000 description 3
239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 3
241000282567 Macaca fascicularis Species 0.000 description 3
206010025421 Macule Diseases 0.000 description 3
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 3
239000004743 Polypropylene Substances 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108010048673 Vitronectin Receptors Proteins 0.000 description 3
150000001242 acetic acid derivatives Chemical class 0.000 description 3
229910045601 alloy Inorganic materials 0.000 description 3
239000000956 alloy Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000000544 cholinesterase inhibitor Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000004154 complement system Effects 0.000 description 3
238000011109 contamination Methods 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
229940043075 fluocinolone Drugs 0.000 description 3
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
238000011010 flushing procedure Methods 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
229960004716 idoxuridine Drugs 0.000 description 3
229960000905 indomethacin Drugs 0.000 description 3
238000007913 intrathecal administration Methods 0.000 description 3
229940043355 kinase inhibitor Drugs 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
229940092110 macugen Drugs 0.000 description 3
229960001929 meloxicam Drugs 0.000 description 3
239000002105 nanoparticle Substances 0.000 description 3
229960001002 nepafenac Drugs 0.000 description 3
QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000000737 periodic effect Effects 0.000 description 3
239000003757 phosphotransferase inhibitor Substances 0.000 description 3
229960002702 piroxicam Drugs 0.000 description 3
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
229920001155 polypropylene Polymers 0.000 description 3
229940068977 polysorbate 20 Drugs 0.000 description 3
239000005373 porous glass Substances 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000036573 scar formation Effects 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
238000010998 test method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
238000009736 wetting Methods 0.000 description 3
NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 2
RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
PCNWSHKCOYOECO-UHFFFAOYSA-N 1-methylsulfonyl-4-(1-phenylethyl)benzene Chemical compound CS(=O)(=O)C1=CC=C(C=C1)C(C)C1=CC=CC=C1 PCNWSHKCOYOECO-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 2
GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 description 2
XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 2
102400000068 Angiostatin Human genes 0.000 description 2
108010079709 Angiostatins Proteins 0.000 description 2
229940088872 Apoptosis inhibitor Drugs 0.000 description 2
108010082340 Arginine deiminase Proteins 0.000 description 2
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
102400000730 Canstatin Human genes 0.000 description 2
101800000626 Canstatin Proteins 0.000 description 2
102000053642 Catalytic RNA Human genes 0.000 description 2
108090000994 Catalytic RNA Proteins 0.000 description 2
208000002177 Cataract Diseases 0.000 description 2
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
229920004943 Delrin® Polymers 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
102400001047 Endostatin Human genes 0.000 description 2
108010079505 Endostatins Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
108010008165 Etanercept Proteins 0.000 description 2
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010086677 Gonadotropins Proteins 0.000 description 2
102000006771 Gonadotropins Human genes 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
102000012355 Integrin beta1 Human genes 0.000 description 2
108010022222 Integrin beta1 Proteins 0.000 description 2
102000008607 Integrin beta3 Human genes 0.000 description 2
108010020950 Integrin beta3 Proteins 0.000 description 2
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
101100481410 Mus musculus Tek gene Proteins 0.000 description 2
QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 2
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
208000022873 Ocular disease Diseases 0.000 description 2
239000004696 Poly ether ether ketone Substances 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
229920002385 Sodium hyaluronate Polymers 0.000 description 2
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 2
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 2
102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 2
108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 2
229920006356 Teflon™ FEP Polymers 0.000 description 2
229940123464 Thiazolidinedione Drugs 0.000 description 2
102400000731 Tumstatin Human genes 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
108091008605 VEGF receptors Proteins 0.000 description 2
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 2
102000002852 Vasopressins Human genes 0.000 description 2
108010004977 Vasopressins Proteins 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
229960002964 adalimumab Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002870 angiogenesis inducing agent Substances 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000000158 apoptosis inhibitor Substances 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
229960004574 azelastine Drugs 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
238000005452 bending Methods 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
229960001467 bortezomib Drugs 0.000 description 2
229960000722 brinzolamide Drugs 0.000 description 2
HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 2
229960000830 captopril Drugs 0.000 description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
229960005110 cerivastatin Drugs 0.000 description 2
229960001803 cetirizine Drugs 0.000 description 2
229960005395 cetuximab Drugs 0.000 description 2
229960003291 chlorphenamine Drugs 0.000 description 2
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 2
239000011651 chromium Substances 0.000 description 2
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229960001338 colchicine Drugs 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
229960003957 dexamethasone Drugs 0.000 description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000012990 dithiocarbamate Substances 0.000 description 2
IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
229960001850 droxicam Drugs 0.000 description 2
OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
229960000403 etanercept Drugs 0.000 description 2
238000005530 etching Methods 0.000 description 2
229960005293 etodolac Drugs 0.000 description 2
XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 2
229960001419 fenoprofen Drugs 0.000 description 2
229960004369 flufenamic acid Drugs 0.000 description 2
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 2
229960000936 fumagillin Drugs 0.000 description 2
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 2
230000006870 function Effects 0.000 description 2
229940074391 gallic acid Drugs 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000002622 gonadotropin Substances 0.000 description 2
239000000938 histamine H1 antagonist Substances 0.000 description 2
239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
239000003395 histamine H3 receptor antagonist Substances 0.000 description 2
239000003396 histamine H4 receptor antagonist Substances 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000008798 inflammatory stress Effects 0.000 description 2
229960000598 infliximab Drugs 0.000 description 2
208000014674 injury Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
102000006495 integrins Human genes 0.000 description 2
108010044426 integrins Proteins 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
229950002252 isoxicam Drugs 0.000 description 2
YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
229960000991 ketoprofen Drugs 0.000 description 2
229960004891 lapatinib Drugs 0.000 description 2
150000002605 large molecules Chemical class 0.000 description 2
238000002386 leaching Methods 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 2
229960002202 lornoxicam Drugs 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
229960003803 meclofenamic acid Drugs 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960003464 mefenamic acid Drugs 0.000 description 2
HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229960002009 naproxen Drugs 0.000 description 2
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
229960002739 oxaprozin Drugs 0.000 description 2
OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229960001972 panitumumab Drugs 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
229960004662 parecoxib Drugs 0.000 description 2
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229960001476 pentoxifylline Drugs 0.000 description 2
229960002582 perindopril Drugs 0.000 description 2
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 2
230000035699 permeability Effects 0.000 description 2
230000000649 photocoagulation Effects 0.000 description 2
238000002428 photodynamic therapy Methods 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
229920002530 polyetherether ketone Polymers 0.000 description 2
229920005597 polymer membrane Polymers 0.000 description 2
229920001343 polytetrafluoroethylene Polymers 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
210000003488 posterior eye segment Anatomy 0.000 description 2
IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
239000003450 potassium channel blocker Substances 0.000 description 2
229960005205 prednisolone Drugs 0.000 description 2
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
150000005599 propionic acid derivatives Chemical class 0.000 description 2
150000003180 prostaglandins Chemical class 0.000 description 2
238000002731 protein assay Methods 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
229960001455 quinapril Drugs 0.000 description 2
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
235000010413 sodium alginate Nutrition 0.000 description 2
239000000661 sodium alginate Substances 0.000 description 2
229940005550 sodium alginate Drugs 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229940010747 sodium hyaluronate Drugs 0.000 description 2
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
229960003787 sorafenib Drugs 0.000 description 2
229950001248 squalamine Drugs 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000126 substance Substances 0.000 description 2
229960001796 sunitinib Drugs 0.000 description 2
WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
229960002871 tenoxicam Drugs 0.000 description 2
WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 2
BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 description 2
229940126585 therapeutic drug Drugs 0.000 description 2
150000001467 thiazolidinediones Chemical class 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
229960002905 tolfenamic acid Drugs 0.000 description 2
YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 2
229960000575 trastuzumab Drugs 0.000 description 2
230000008733 trauma Effects 0.000 description 2
MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
230000005740 tumor formation Effects 0.000 description 2
229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 2
239000002451 tumor necrosis factor inhibitor Substances 0.000 description 2
108010012374 type IV collagen alpha3 chain Proteins 0.000 description 2
229960002004 valdecoxib Drugs 0.000 description 2
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 2
229960003726 vasopressin Drugs 0.000 description 2
229940099039 velcade Drugs 0.000 description 2
YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 2
229940061392 visudyne Drugs 0.000 description 2
QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
ZDRRIRUAESZNIH-BZGUUIOASA-N (2s)-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-10-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]- Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZDRRIRUAESZNIH-BZGUUIOASA-N 0.000 description 1
QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
HUQJRYMLJBBEDO-UHFFFAOYSA-N (5-chloro-1h-indol-2-yl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC2=CC(Cl)=CC=C2N1 HUQJRYMLJBBEDO-UHFFFAOYSA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
KOTJFAYEELTYCZ-BTJKTKAUSA-N (z)-but-2-enedioic acid;(6-chloro-1h-benzimidazol-2-yl)-(4-methylpiperazin-1-yl)methanone Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCN1C(=O)C1=NC2=CC(Cl)=CC=C2N1 KOTJFAYEELTYCZ-BTJKTKAUSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 description 1
QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
AQOKCDNYWBIDND-ABRBVVEGSA-N 5-trans-17-phenyl trinor Prostaglandin F2alpha ethyl amide Chemical compound CCNC(=O)CCC\C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-ABRBVVEGSA-N 0.000 description 1
NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
NOESYZHRGYRDHS-ZYCCASTOSA-N 8a-l-threonine-10a-l-isoleucine-insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 NOESYZHRGYRDHS-ZYCCASTOSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108010058207 Anistreplase Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 description 1
101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 description 1
101150071146 COX2 gene Proteins 0.000 description 1
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
102400000113 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
239000004099 Chlortetracycline Substances 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
229910000684 Cobalt-chrome Inorganic materials 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000001493 Cyclophilins Human genes 0.000 description 1
108010068682 Cyclophilins Proteins 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
101100481404 Danio rerio tie1 gene Proteins 0.000 description 1
108010019673 Darbepoetin alfa Proteins 0.000 description 1
ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
102400001099 Endorepellin Human genes 0.000 description 1
101800001739 Endorepellin Proteins 0.000 description 1
108010032976 Enfuvirtide Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
108010074604 Epoetin Alfa Proteins 0.000 description 1
108010056764 Eptifibatide Proteins 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010011459 Exenatide Proteins 0.000 description 1
HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
206010015943 Eye inflammation Diseases 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102100037362 Fibronectin Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
108010072051 Glatiramer Acetate Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
108010026389 Gramicidin Proteins 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000620009 Homo sapiens Polyunsaturated fatty acid 5-lipoxygenase Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
102100029199 Iduronate 2-sulfatase Human genes 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108010065920 Insulin Lispro Proteins 0.000 description 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
102100040018 Interferon alpha-2 Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010079944 Interferon-alpha2b Proteins 0.000 description 1
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
201000010538 Lactose Intolerance Diseases 0.000 description 1
KMZQAVXSMUKBPD-DJWKRKHSSA-N Lafutidine Chemical compound C=1C=COC=1C[S+]([O-])CC(=O)NC\C=C/COC(N=CC=1)=CC=1CN1CCCCC1 KMZQAVXSMUKBPD-DJWKRKHSSA-N 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
101100046669 Mus musculus Tox gene Proteins 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010061876 Obstruction Diseases 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
108700006640 OspA Proteins 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
101150000187 PTGS2 gene Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004695 Polyether sulfone Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 1
206010067268 Post procedural infection Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000037111 Retinal Hemorrhage Diseases 0.000 description 1
201000007737 Retinal degeneration Diseases 0.000 description 1
206010057430 Retinal injury Diseases 0.000 description 1
206010038910 Retinitis Diseases 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
SMTZFNFIKUPEJC-UHFFFAOYSA-N Roxane Chemical compound CC(=O)OCC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1 SMTZFNFIKUPEJC-UHFFFAOYSA-N 0.000 description 1
QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
108010039185 Tenecteplase Proteins 0.000 description 1
108010049264 Teriparatide Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
108010057266 Type A Botulinum Toxins Proteins 0.000 description 1
108010047196 Urofollitropin Proteins 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
108010031318 Vitronectin Proteins 0.000 description 1
102100035140 Vitronectin Human genes 0.000 description 1
JPKKQJKQTPNWTR-BRYCGAMXSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-BRYCGAMXSA-N 0.000 description 1
DPHFJXVKASDMBW-RQRKFSSASA-N [2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate;hydrate Chemical compound O.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O DPHFJXVKASDMBW-RQRKFSSASA-N 0.000 description 1
JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 description 1
WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
229960002184 abarelix Drugs 0.000 description 1
108010023617 abarelix Proteins 0.000 description 1
AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
229960003697 abatacept Drugs 0.000 description 1
229960000446 abciximab Drugs 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
KFHYZKCRXNRKRC-MRXNPFEDSA-N abt-239 Chemical compound C[C@@H]1CCCN1CCC1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2O1 KFHYZKCRXNRKRC-MRXNPFEDSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
229960004266 acetylcholine chloride Drugs 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229960002833 aflibercept Drugs 0.000 description 1
108010081667 aflibercept Proteins 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
229960002459 alefacept Drugs 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
229940003677 alphagan Drugs 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
229960000983 anistreplase Drugs 0.000 description 1
229960002469 antazoline Drugs 0.000 description 1
REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
230000003510 anti-fibrotic effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000003431 anti-prostaglandin Effects 0.000 description 1
230000001494 anti-thymocyte effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960002028 atropine sulfate Drugs 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
229960003005 axitinib Drugs 0.000 description 1
RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
229960004669 basiliximab Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
229940098085 betagan Drugs 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229960004324 betaxolol Drugs 0.000 description 1
NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
108010055460 bivalirudin Proteins 0.000 description 1
229960001500 bivalirudin Drugs 0.000 description 1
OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229940094657 botulinum toxin type a Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960003679 brimonidine Drugs 0.000 description 1
229960003655 bromfenac Drugs 0.000 description 1
ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229950001178 capromab Drugs 0.000 description 1
229960004484 carbachol Drugs 0.000 description 1
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
229960003230 cetrorelix Drugs 0.000 description 1
108700008462 cetrorelix Proteins 0.000 description 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
WMEMLXDTLKSUOD-OGCOPIPOSA-N chembl436844 Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@@H](CC=2C3=CC=CC=C3N(C)C=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](C)C(=O)N1)C(C)C)=O)NC(=O)[C@@H](NC(C)=O)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 WMEMLXDTLKSUOD-OGCOPIPOSA-N 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
229960004475 chlortetracycline Drugs 0.000 description 1
CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
210000004240 ciliary body Anatomy 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960003405 ciprofloxacin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229960002881 clemastine Drugs 0.000 description 1
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical group CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000010952 cobalt-chrome Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
239000004074 complement inhibitor Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
229940038717 copaxone Drugs 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
229960005029 darbepoetin alfa Drugs 0.000 description 1
229960002448 dasatinib Drugs 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
229960004120 defibrotide Drugs 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000011118 depth filtration Methods 0.000 description 1
229960001271 desloratadine Drugs 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
229960003657 dexamethasone acetate Drugs 0.000 description 1
VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
229960001992 dimetindene Drugs 0.000 description 1
MVMQESMQSYOVGV-UHFFFAOYSA-N dimetindene Chemical compound CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 MVMQESMQSYOVGV-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229960000533 dornase alfa Drugs 0.000 description 1
108010067396 dornase alfa Proteins 0.000 description 1
229960003933 dorzolamide Drugs 0.000 description 1
229960005178 doxylamine Drugs 0.000 description 1
HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
229940056176 drotrecogin alfa Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
238000007923 drug release testing Methods 0.000 description 1
208000011325 dry age related macular degeneration Diseases 0.000 description 1
229960001971 ebastine Drugs 0.000 description 1
MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 1
OVXQHPWHMXOFRD-UHFFFAOYSA-M ecothiopate iodide Chemical compound [I-].CCOP(=O)(OCC)SCC[N+](C)(C)C OVXQHPWHMXOFRD-UHFFFAOYSA-M 0.000 description 1
229960002224 eculizumab Drugs 0.000 description 1
229960000284 efalizumab Drugs 0.000 description 1
229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
229950000472 embramine Drugs 0.000 description 1
URSRSKSNFPUKGH-UHFFFAOYSA-N embramine Chemical compound C=1C=C(Br)C=CC=1C(C)(OCCN(C)C)C1=CC=CC=C1 URSRSKSNFPUKGH-UHFFFAOYSA-N 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
229960002062 enfuvirtide Drugs 0.000 description 1
PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
229960003388 epoetin alfa Drugs 0.000 description 1
229960004468 eptifibatide Drugs 0.000 description 1
GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
229960001433 erlotinib Drugs 0.000 description 1
AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
229950002420 eucatropine Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229960005167 everolimus Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229960001519 exenatide Drugs 0.000 description 1
229960001596 famotidine Drugs 0.000 description 1
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
229950003662 fenretinide Drugs 0.000 description 1
229960003592 fexofenadine Drugs 0.000 description 1
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
238000005429 filling process Methods 0.000 description 1
229960001048 fluorometholone Drugs 0.000 description 1
FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960000578 gemtuzumab Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000011491 glass wool Substances 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229960002913 goserelin Drugs 0.000 description 1
229960004905 gramicidin Drugs 0.000 description 1
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
208000037824 growth disorder Diseases 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000004371 high visual acuity Effects 0.000 description 1
229960000857 homatropine Drugs 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
229960001067 hydrocortisone acetate Drugs 0.000 description 1
229950005360 hydroxyamfetamine Drugs 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
108010072166 idursulfase Proteins 0.000 description 1
229960002396 idursulfase Drugs 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000012966 insertion method Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
229960002068 insulin lispro Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
229960003303 lafutidine Drugs 0.000 description 1
229960004408 lepirudin Drugs 0.000 description 1
OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
229960000831 levobunolol Drugs 0.000 description 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 1
229960001508 levocetirizine Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229960003088 loratadine Drugs 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
229960000994 lumiracoxib Drugs 0.000 description 1
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
238000003754 machining Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229960001474 meclozine Drugs 0.000 description 1
FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
229960004083 methazolamide Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000000693 micelle Substances 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003547 miosis Effects 0.000 description 1
239000003604 miotic agent Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002911 mydriatic effect Effects 0.000 description 1
LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
229960004270 nabumetone Drugs 0.000 description 1
229960005016 naphazoline Drugs 0.000 description 1
229960005027 natalizumab Drugs 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
229960001267 nesiritide Drugs 0.000 description 1
HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
229940080607 nexavar Drugs 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
229910001000 nickel titanium Inorganic materials 0.000 description 1
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
229960001346 nilotinib Drugs 0.000 description 1
HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960001907 nitrofurazone Drugs 0.000 description 1
229960004872 nizatidine Drugs 0.000 description 1
SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
238000009659 non-destructive testing Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
229960004114 olopatadine Drugs 0.000 description 1
JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
229960000470 omalizumab Drugs 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036407 pain Effects 0.000 description 1
229960000402 palivizumab Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229960000639 pazopanib Drugs 0.000 description 1
CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
229960001218 pegademase Drugs 0.000 description 1
108010027841 pegademase bovine Proteins 0.000 description 1
229960001744 pegaspargase Drugs 0.000 description 1
108010001564 pegaspargase Proteins 0.000 description 1
229960001373 pegfilgrastim Drugs 0.000 description 1
108010044644 pegfilgrastim Proteins 0.000 description 1
108010092853 peginterferon alfa-2a Proteins 0.000 description 1
229960003930 peginterferon alfa-2a Drugs 0.000 description 1
108010092851 peginterferon alfa-2b Proteins 0.000 description 1
229960003931 peginterferon alfa-2b Drugs 0.000 description 1
229960002995 pegvisomant Drugs 0.000 description 1
108700037519 pegvisomant Proteins 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229960001190 pheniramine Drugs 0.000 description 1
229960001802 phenylephrine Drugs 0.000 description 1
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
229940100008 phospholine iodide Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000003504 photosensitizing agent Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001416 pilocarpine Drugs 0.000 description 1
KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
229960005330 pimecrolimus Drugs 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920006393 polyether sulfone Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229940125422 potassium channel blocker Drugs 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229960003611 pramlintide Drugs 0.000 description 1
108010029667 pramlintide Proteins 0.000 description 1
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
239000002243 precursor Substances 0.000 description 1
JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000003825 pressing Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001072 progestational effect Effects 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
229960003910 promethazine Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000424 rasburicase Drugs 0.000 description 1
108010084837 rasburicase Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000004627 regenerated cellulose Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
230000004258 retinal degeneration Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
229960003320 roxatidine Drugs 0.000 description 1
150000003872 salicylic acid derivatives Chemical group 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
MEGPURSNXMUDAE-RLMOJYMMSA-N scopoline Chemical compound C([C@H](O1)C2)[C@@H]3N(C)[C@H]2[C@H]1[C@H]3O MEGPURSNXMUDAE-RLMOJYMMSA-N 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
229960002758 sermorelin Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000005245 sintering Methods 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
229960003212 sodium propionate Drugs 0.000 description 1
239000004324 sodium propionate Substances 0.000 description 1
235000010334 sodium propionate Nutrition 0.000 description 1
239000007779 soft material Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
229960002673 sulfacetamide Drugs 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
229960000654 sulfafurazole Drugs 0.000 description 1
VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
229960005158 sulfamethizole Drugs 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229940034785 sutent Drugs 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229940037128 systemic glucocorticoids Drugs 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229960000235 temsirolimus Drugs 0.000 description 1
229960000216 tenecteplase Drugs 0.000 description 1
229960005460 teriparatide Drugs 0.000 description 1
OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960000337 tetryzoline Drugs 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
229960005221 timolol maleate Drugs 0.000 description 1
229940034744 timoptic Drugs 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
229960005267 tositumomab Drugs 0.000 description 1
230000007704 transition Effects 0.000 description 1
229940113006 travatan Drugs 0.000 description 1
229960002368 travoprost Drugs 0.000 description 1
229940126307 triamcinolone acetate Drugs 0.000 description 1
229940038017 triesence Drugs 0.000 description 1
VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
229960003962 trifluridine Drugs 0.000 description 1
229960004791 tropicamide Drugs 0.000 description 1
229940108420 trusopt Drugs 0.000 description 1
229940094060 tykerb Drugs 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960004371 urofollitropin Drugs 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
229960000241 vandetanib Drugs 0.000 description 1
UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000003466 welding Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229960005332 zileuton Drugs 0.000 description 1
MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
229950009819 zotarolimus Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

JP2013523372A 2010-08-05 2011-08-05 組み合わせ薬物送達方法および装置 Active JP6111194B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US37116810P	2010-08-05	2010-08-05
US61/371,168		2010-08-05
PCT/US2011/046817 WO2012019139A1 (en)	2010-08-05	2011-08-05	Combined drug delivery methods and apparatus

Publications (3)

Publication Number	Publication Date
JP2013538082A JP2013538082A (ja)	2013-10-10
JP2013538082A5 JP2013538082A5 (zh)	2014-09-25
JP6111194B2 true JP6111194B2 (ja)	2017-04-05

Family

ID=45559845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2013523372A Active JP6111194B2 (ja)	2010-08-05	2011-08-05	組み合わせ薬物送達方法および装置

Country Status (7)

Country	Link
US (2)	US10617557B2 (zh)
EP (1)	EP2600876B1 (zh)
JP (1)	JP6111194B2 (zh)
CN (1)	CN103153316B (zh)
AU (1)	AU2011285548B2 (zh)
CA (1)	CA2807537C (zh)
WO (1)	WO2012019139A1 (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8623395B2 (en)	2010-01-29	2014-01-07	Forsight Vision4, Inc.	Implantable therapeutic device
EP2600876B1 (en) *	2010-08-05	2015-04-29	Forsight Vision4, Inc.	Combined drug delivery methods and apparatus
CN103209733B (zh)	2010-08-05	2015-12-16	弗赛特影像4股份有限公司	用于药物输送的注入器装置和方法
CA2818612C (en)	2010-11-19	2020-12-29	Forsight Vision4, Inc.	Therapeutic agent formulations for implanted devices
EP4249059A3 (en)	2011-06-28	2023-11-29	ForSight Vision4, Inc.	An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
US9883968B2 (en)	2011-09-16	2018-02-06	Forsight Vision4, Inc.	Fluid exchange apparatus and methods
WO2013116061A1 (en)	2012-02-03	2013-08-08	Forsight Vision4, Inc.	Insertion and removal methods and apparatus for therapeutic devices
CA2905496A1 (en) *	2013-03-14	2014-09-25	Forsight Vision4, Inc.	Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2907681C (en)	2013-03-28	2022-11-22	Forsight Vision4, Inc.	Ophthalmic implant for delivering therapeutic substances
WO2015196055A1 (en) *	2014-06-19	2015-12-23	California Institute Of Technology	Small molecule transport device for drug delivery or waste removal
WO2016011191A1 (en)	2014-07-15	2016-01-21	Forsight Vision4, Inc.	Ocular implant delivery device and method
RU2017105844A (ru)	2014-08-08	2018-09-11	Форсайт Вижн4, Инк.	Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
US10507101B2 (en)	2014-10-13	2019-12-17	W. L. Gore & Associates, Inc.	Valved conduit
KR20170106298A (ko)	2014-11-10	2017-09-20	포사이트 비젼4, 인크.	확장 가능한 약물 전달 장치 및 이용 방법
US10842916B2 (en) *	2015-06-24	2020-11-24	Healionics Corporation	Injectable porous device for treatment of dry and wet age-related macular degeneration or diabetic retinopathy
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
ES2908479T3 (es)	2015-08-26	2022-04-29	Achillion Pharmaceuticals Inc	Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios
US11013403B2 (en)	2015-09-29	2021-05-25	The Regents Of The University Of California	Methods of diagnosing diseases of mucosal surfaces
US11432959B2 (en)	2015-11-20	2022-09-06	Forsight Vision4, Inc.	Porous structures for extended release drug delivery devices
AU2017246889B2 (en)	2016-04-05	2021-12-16	Forsight Vision4, Inc.	Implantable ocular drug delivery devices
WO2018005552A1 (en)	2016-06-27	2018-01-04	Achillion Pharmaceuticals, Inc.	Quinazoline and indole compounds to treat medical disorders
EP3589628A4 (en)	2017-03-01	2021-03-31	Achillion Pharmaceuticals, Inc.	ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISEASES
US11351058B2 (en)	2017-03-17	2022-06-07	W. L. Gore & Associates, Inc.	Glaucoma treatment systems and methods
CA3066055A1 (en) *	2017-06-14	2018-12-20	Semma Therapeutics, Inc.	Devices and methods for delivering therapeutics
CA3082891A1 (en)	2017-11-21	2019-05-31	Forsight Vision4, Inc.	Fluid exchange apparatus for expandable port delivery system and methods of use
WO2019191112A1 (en)	2018-03-26	2019-10-03	C4 Therapeutics, Inc.	Cereblon binders for the degradation of ikaros
US20230022157A1 (en)	2018-08-20	2023-01-26	Achillion Pharmaceuticals, Inc.	Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7504088B2 (ja)	2018-10-16	2024-06-21	ジョージアステイトユニバーシティーリサーチファウンデーションインコーポレイテッド	医学的障害の治療のための一酸化炭素プロドラッグ
US11678983B2 (en)	2018-12-12	2023-06-20	W. L. Gore & Associates, Inc.	Implantable component with socket
US20220249281A1 (en) *	2019-07-26	2022-08-11	Tohoku University	Continual drug release device that can be replenished with drugs
TW202146412A (zh)	2020-03-05	2021-12-16	美商Ｃ４醫藥公司	用於標靶降解brd9之化合物
USD1033637S1 (en)	2022-01-24	2024-07-02	Forsight Vision4, Inc.	Fluid exchange device

Family Cites Families (392)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2585815A (en)	1947-01-16	1952-02-12	Mclintock Duncan Menzies	Injection syringe
US2564977A (en)	1949-01-19	1951-08-21	Hu Quang Hsi	Medical injecting apparatus
US2886497A (en)	1957-04-12	1959-05-12	United States Steel Corp	Method for determining the permeability of steel to hydrogen
US3232117A (en)	1962-09-14	1966-02-01	Roger Gilmont Instr Inc	Micrometer buret
US3416530A (en)	1966-03-02	1968-12-17	Richard A. Ness	Eyeball medication dispensing tablet
US3618604A (en)	1969-06-09	1971-11-09	Alza Corp	Ocular insert
US3641237A (en)	1970-09-30	1972-02-08	Nat Patent Dev Corp	Zero order release constant elution rate drug dosage
US4034756A (en)	1971-01-13	1977-07-12	Alza Corporation	Osmotically driven fluid dispenser
US3831583A (en)	1971-03-05	1974-08-27	Univ California	Implantable bulb for inflation of surgical implements
US3995635A (en)	1971-09-09	1976-12-07	Alza Corporation	Ocular insert
US3828777A (en)	1971-11-08	1974-08-13	Alza Corp	Microporous ocular device
US3845201A (en)	1972-04-24	1974-10-29	S Loucas	Solid state ophthalmic medication delivery method
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US3914402A (en)	1973-06-14	1975-10-21	Alza Corp	Ophthalmic dosage form, for releasing medication over time
US4179497A (en)	1973-12-17	1979-12-18	Merck & Co., Inc.	Solid state ophthalmic medication
US3902495A (en)	1974-01-28	1975-09-02	Cavitron Corp	Flow control system
US3961628A (en)	1974-04-10	1976-06-08	Alza Corporation	Ocular drug dispensing system
US3949748A (en)	1974-09-26	1976-04-13	Oscar Malmin	Injection syringe having aspirating and metering capabilities
US3949750A (en)	1974-10-07	1976-04-13	Freeman Jerre M	Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US3926188A (en)	1974-11-14	1975-12-16	Alza Corp	Laminated drug dispenser
US4093708A (en)	1974-12-23	1978-06-06	Alza Corporation	Osmotic releasing device having a plurality of release rate patterns
US4014335A (en)	1975-04-21	1977-03-29	Alza Corporation	Ocular drug delivery device
NL188266C (nl)	1975-07-29	1992-05-18	Merck & Co Inc	Werkwijze ter bereiding van een oogheelkundig inplantaat.
US3977404A (en)	1975-09-08	1976-08-31	Alza Corporation	Osmotic device having microporous reservoir
US4034758A (en)	1975-09-08	1977-07-12	Alza Corporation	Osmotic therapeutic system for administering medicament
US4014333A (en)	1975-09-22	1977-03-29	Mcintyre David J	Instrument for aspirating and irrigating during ophthalmic surgery
US4077407A (en)	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4014334A (en)	1976-02-02	1977-03-29	Alza Corporation	Laminated osmotic system for dispensing beneficial agent
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system with means for improving delivery kinetics of system
US4111201A (en)	1976-11-22	1978-09-05	Alza Corporation	Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4160452A (en)	1977-04-07	1979-07-10	Alza Corporation	Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4164559A (en)	1977-09-21	1979-08-14	Cornell Research Foundation, Inc.	Collagen drug delivery device
US4186184A (en)	1977-12-27	1980-01-29	Alza Corporation	Selective administration of drug with ocular therapeutic system
US4220152A (en)	1978-05-08	1980-09-02	Pfizer Inc.	Delivery system
US4220153A (en)	1978-05-08	1980-09-02	Pfizer Inc.	Controlled release delivery system
US4200098A (en)	1978-10-23	1980-04-29	Alza Corporation	Osmotic system with distribution zone for dispensing beneficial agent
US4298000A (en)	1978-11-08	1981-11-03	Minnesota Mining And Manufacturing Company	Fluid dispensing device
US4300557A (en)	1980-01-07	1981-11-17	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method for treating intraocular malignancies
ATE9059T1 (de)	1980-01-28	1984-09-15	Merck & Co. Inc.	Ophthalmische kohlensaure anhydrase-inhibitoren enthaltende einlagen zur verringerung intraokularer hypertension.
US4309776A (en)	1980-05-13	1982-01-12	Ramon Berguer	Intravascular implantation device and method of using the same
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US4484922A (en)	1981-06-25	1984-11-27	Rosenwald Peter L	Occular device
US4439198A (en)	1981-07-09	1984-03-27	University Of Illinois Foundation	Biodegradable ocular insert for controlled delivery of ophthalmic medication
US4730013A (en)	1981-10-08	1988-03-08	Merck & Co., Inc.	Biosoluble ocular insert
US4439196A (en)	1982-03-18	1984-03-27	Merck & Co., Inc.	Osmotic drug delivery system
US4475916A (en)	1982-03-18	1984-10-09	Merck & Co., Inc.	Osmotic drug delivery system
US4519801A (en)	1982-07-12	1985-05-28	Alza Corporation	Osmotic device with wall comprising cellulose ether and permeability enhancer
US4673405A (en)	1983-03-04	1987-06-16	Alza Corporation	Osmotic system with instant drug availability
US4883459A (en)	1983-07-29	1989-11-28	Reynaldo Calderon	Retrograde perfusion
US4774091A (en)	1983-10-14	1988-09-27	Sumitomo Pharmaceuticals Company, Ltd.	Long-term sustained-release preparation
US4627850A (en)	1983-11-02	1986-12-09	Alza Corporation	Osmotic capsule
US4777049A (en)	1983-12-01	1988-10-11	Alza Corporation	Constant release system with pulsed release
US4634418A (en)	1984-04-06	1987-01-06	Binder Perry S	Hydrogel seton
US4851228A (en)	1984-06-20	1989-07-25	Merck & Co., Inc.	Multiparticulate controlled porosity osmotic
US4634427A (en)	1984-09-04	1987-01-06	American Hospital Supply Company	Implantable demand medication delivery assembly
US5049142A (en)	1984-11-07	1991-09-17	Herrick Robert S	Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US5053030A (en)	1984-11-07	1991-10-01	Herrick Robert S	Intracanalicular implant for horizontal canalicular blockade treatment of the eye
US4712550A (en)	1985-04-08	1987-12-15	Sinnett Kevin B	Retinal tack
US4609374A (en)	1985-04-22	1986-09-02	Alza Corporation	Osmotic device comprising means for governing initial time of agent release therefrom
US4693886A (en)	1985-04-22	1987-09-15	Alza Corporation	Osmotic device with inert core
EP0201611A1 (de)	1985-05-10	1986-11-20	B. Braun-SSC AG	Zwei-Kanülen-Spritze
US4781675A (en)	1985-11-27	1988-11-01	White Thomas C	Infusion cannula
EP0228185B1 (en)	1985-11-27	1990-07-25	Thomas C. White	Tissue-implantable fluid-dissipating device
US4959217A (en)	1986-05-22	1990-09-25	Syntex (U.S.A.) Inc.	Delayed/sustained release of macromolecules
US5147647A (en)	1986-10-02	1992-09-15	Sohrab Darougar	Ocular insert for the fornix
US5322691A (en)	1986-10-02	1994-06-21	Sohrab Darougar	Ocular insert with anchoring protrusions
US4863457A (en)	1986-11-24	1989-09-05	Lee David A	Drug delivery device
DE3751871D1 (de)	1986-12-23	1996-09-19	Liposome Co Inc	Guanidinaminoglycosid enthaltende Liposome
US4853229A (en)	1987-10-26	1989-08-01	Alza Corporation	Method for adminstering tiny pills
JP2702953B2 (ja)	1988-01-30	1998-01-26	オリンパス光学工業株式会社	薬液含浸セラミックス
US4865846A (en)	1988-06-03	1989-09-12	Kaufman Herbert E	Drug delivery system
US5174999A (en)	1988-12-13	1992-12-29	Alza Corporation	Delivery system comprising fluid ingress and drug egress
WO1990007575A1 (en)	1988-12-30	1990-07-12	Anderson David M	Stabilized microporous materials and hydrogel materials
US5141748A (en)	1989-02-17	1992-08-25	Hoffmann-La Roche, Inc.	Implant drug delivery device
US5098443A (en)	1989-03-23	1992-03-24	University Of Miami	Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US4979938A (en)	1989-05-11	1990-12-25	Iomed, Inc.	Method of iontophoretically treating acne, furuncles and like skin disorders
US5164188A (en)	1989-11-22	1992-11-17	Visionex, Inc.	Biodegradable ocular implants
US5171270A (en)	1990-03-29	1992-12-15	Herrick Robert S	Canalicular implant having a collapsible flared section and method
US5324280A (en)	1990-04-02	1994-06-28	Alza Corporation	Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5128145A (en)	1990-06-13	1992-07-07	Alza Corporation	Dosage form for Parkinson's disease, spasticity and muscle spasms
US5238687A (en)	1990-07-11	1993-08-24	Alza Corporation	Delivery device with a protective sleeve
US5084021A (en)	1990-11-02	1992-01-28	Baldwin Brian E	Patient controlled infusion apparatus and method
US5378475A (en)	1991-02-21	1995-01-03	University Of Kentucky Research Foundation	Sustained release drug delivery devices
AU650113B2 (en)	1991-04-05	1994-06-09	Eli Lilly And Company	Sustained release capsule and formulations
US5334189A (en)	1991-06-03	1994-08-02	Wade Stephen E	Device for controlled diffusion of a chemical substance
US5282829A (en)	1991-08-15	1994-02-01	United States Surgical Corporation	Hollow body implants
FR2682090B1 (fr)	1991-10-03	1993-12-31	Holzstoff Holding Sa	Systeme-reservoir pour diffusion prolongee d'un principe actif.
US5681572A (en)	1991-10-18	1997-10-28	Seare, Jr.; William J.	Porous material product and process
US5178635A (en)	1992-05-04	1993-01-12	Allergan, Inc.	Method for determining amount of medication in an implantable device
US6096756A (en)	1992-09-21	2000-08-01	Albert Einstein College Of Medicine Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5336175A (en)	1992-10-29	1994-08-09	Mames Robert N	Method for the treatment of retinal detachments
US5443505A (en)	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
CA2140053C (en)	1994-02-09	2000-04-04	Joel S. Rosenblatt	Collagen-based injectable drug delivery system and its use
US5770076A (en)	1994-03-07	1998-06-23	The Regents Of The University Of California	Micromachined capsules having porous membranes and bulk supports
US5985328A (en)	1994-03-07	1999-11-16	Regents Of The University Of California	Micromachined porous membranes with bulk support
US5578042A (en)	1994-03-14	1996-11-26	Cumming; J. Stuart	Ophthalmic kit and method for lens insertion
US5466233A (en)	1994-04-25	1995-11-14	Escalon Ophthalmics, Inc.	Tack for intraocular drug delivery and method for inserting and removing same
AUPM897594A0 (en)	1994-10-25	1994-11-17	Daratech Pty Ltd	Controlled release container
DK0788351T3 (da)	1994-11-10	2003-05-26	Univ Kentucky Res Found	Implanterbar, genopfyldelig anordning til hastighedsreguleret lægemiddeladministration direkte til en indre del af kroppen
US5725493A (en)	1994-12-12	1998-03-10	Avery; Robert Logan	Intravitreal medicine delivery
US5554132A (en)	1995-03-30	1996-09-10	Abbott Laboratories	Hand grip for use with syringe
IL113723A (en)	1995-05-14	2002-11-10	Optonol Ltd	Intraocular implant
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
US5773019A (en)	1995-09-27	1998-06-30	The University Of Kentucky Research Foundation	Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6641708B1 (en)	1996-01-31	2003-11-04	Board Of Regents, The University Of Texas System	Method and apparatus for fractionation using conventional dielectrophoresis and field flow fractionation
GB2310149A (en)	1996-02-15	1997-08-20	Nomix Chipman Ltd	Spray gun
US20090005864A1 (en)	1996-03-18	2009-01-01	Eggleston Harry C	Modular intraocular implant
US5951512A (en)	1996-05-28	1999-09-14	Horizon Medical Products, Inc.	Infusion port with modified drug reservoir
US5797898A (en)	1996-07-02	1998-08-25	Massachusetts Institute Of Technology	Microchip drug delivery devices
US5928662A (en)	1996-07-31	1999-07-27	Phillips; Andrew F.	Ocular drug delivery device
AU7533696A (en)	1996-12-13	1998-06-18	Ciba-Geigy Ag	New materials
PT973499E (pt)	1997-03-31	2003-12-31	Alza Corp	Sistema de administracao difusor implantavel
US7160687B1 (en)	1997-05-29	2007-01-09	Cellomics, Inc.	Miniaturized cell array methods and apparatus for cell-based screening
US5968008A (en)	1997-08-04	1999-10-19	Grams; Guenter A.	Cannula with parallel channels and sliding sheath
US5902598A (en)	1997-08-28	1999-05-11	Control Delivery Systems, Inc.	Sustained release drug delivery devices
US6331523B1 (en)	1998-03-12	2001-12-18	Genentech, Inc.	Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6196993B1 (en)	1998-04-20	2001-03-06	Eyelab Group, Llc	Ophthalmic insert and method for sustained release of medication to the eye
FR2784296B1 (fr)	1998-09-18	2001-01-05	Imedex Biomateriaux	Dispositif pour la formulation et la delivrance d'un melange, notamment pour l'application chirurgicale de ce melange
US7973068B2 (en)	1998-10-20	2011-07-05	Omeros Corporation	Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
DE19948783C2 (de)	1999-02-18	2001-06-13	Alcove Surfaces Gmbh	Implantat
US7914442B1 (en)	1999-03-01	2011-03-29	Gazdzinski Robert F	Endoscopic smart probe and method
US20050119601A9 (en) *	1999-04-26	2005-06-02	Lynch Mary G.	Shunt device and method for treating glaucoma
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6472162B1 (en)	1999-06-04	2002-10-29	Thermogenesis Corp.	Method for preparing thrombin for use in a biological glue
DK1187617T3 (da)	1999-06-18	2004-04-13	Alcon Mfg Ltd	Fremgangsmåde til at vælge koncentrationen af et amfipatisk antihistaminlægemiddel ved at bestemme lægemidlets overfladeaktivitetsmåltal
US6638263B1 (en)	1999-10-12	2003-10-28	Durect Corporation	Regulation of drug delivery through flow diversion
WO2001028473A1 (en) *	1999-10-21	2001-04-26	Alcon Universal Ltd.	Sub-tenon drug delivery
US6416777B1 (en)	1999-10-21	2002-07-09	Alcon Universal Ltd.	Ophthalmic drug delivery device
CN1292721C (zh)	1999-10-21	2007-01-03	爱尔康公司	药物释放装置
US6331313B1 (en)	1999-10-22	2001-12-18	Oculex Pharmaceticals, Inc.	Controlled-release biocompatible ocular drug delivery implant devices and methods
US20030212383A1 (en)	2001-01-05	2003-11-13	Dana Cote	System and methods for reducing intraocular pressure
US20050119737A1 (en)	2000-01-12	2005-06-02	Bene Eric A.	Ocular implant and methods for making and using same
NZ520099A (en)	2000-01-12	2005-03-24	Becton Dickinson Co	Systems and methods for reducing intraocular pressure
DE10008826C2 (de)	2000-02-25	2002-03-14	Disetronic Licensing Ag	Mikroperfusionsvorrichtung mit Sammelbehältnis
US7077848B1 (en)	2000-03-11	2006-07-18	John Hopkins University	Sutureless occular surgical methods and instruments for use in such methods
EP1186439A4 (en)	2000-03-13	2004-12-08	Seiko Epson Corp	SURFACE TREATMENT METHOD, SURFACE TREATED ARTICLE AND SURFACE TREATMENT DEVICE
US7141152B2 (en)	2000-03-16	2006-11-28	Le Febre David A	Analyte species separation system
US6375972B1 (en)	2000-04-26	2002-04-23	Control Delivery Systems, Inc.	Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CA2420038C (en) *	2000-08-30	2010-11-09	John Hopkins University	Devices for intraocular drug delivery
ATE380042T1 (de)	2000-09-06	2007-12-15	Alcon Inc	Beschichtungsmittel mit veränderbarer klebrigkeit für augenimplantate
US6303290B1 (en)	2000-09-13	2001-10-16	The Trustees Of The University Of Pennsylvania	Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process
CA2434156A1 (en)	2000-12-29	2002-07-25	Bausch & Lomb Incorporated	Sustained release drug delivery devices
CA2432225C (en)	2001-01-03	2008-01-15	Michael J. Brubaker	Sustained release drug delivery devices with prefabricated permeable plugs
EP1404295B1 (en)	2001-01-03	2007-10-10	Bausch & Lomb Incorporated	Sustained release drug delivery devices with coated drug cores
DE60137542D1 (de)	2001-01-03	2009-03-12	Bausch & Lomb	Wirkstoffabgabevorrichtungen mit verzögerter freisetzung mehrere stoffe enthaltend
CA2432438C (en)	2001-01-09	2011-04-26	Microchips, Inc.	Flexible microchip devices for ophthalmic and other applications
US6872198B1 (en)	2001-01-24	2005-03-29	Arrow International, Inc.	Double-y-shaped multi-lumen catheter with selectively attachable hubs
CA2433528A1 (en)	2001-01-26	2002-08-01	Bausch & Lomb Incorporated	Improved process for the production of sustained release drug delivery devices
US7181287B2 (en)	2001-02-13	2007-02-20	Second Sight Medical Products, Inc.	Implantable drug delivery device
FR2821672B1 (fr)	2001-03-02	2003-05-02	Scp Dosagene R & D	Moyens pour l'extraction de produits a analyser et leurs applications en diagnostic et analyse
US6713081B2 (en)	2001-03-15	2004-03-30	The United States Of America As Represented By The Department Of Health And Human Services	Ocular therapeutic agent delivery devices and methods for making and using such devices
EP2316394B1 (en)	2001-06-12	2016-11-23	The Johns Hopkins University	Reservoir device for intraocular drug delivery
IL159715A0 (en)	2001-07-10	2004-06-20	Teva Pharma	Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
IL144446A0 (en)	2001-07-19	2002-05-23	Prochon Biotech Ltd	Plasma protein matrices and methods for their preparation
CA2446741C (en)	2001-07-23	2009-09-29	Alcon, Inc.	Ophthalmic drug delivery device
JP4261343B2 (ja)	2001-07-23	2009-04-30	アルコン，インコーポレイティド	眼薬投与装置
ES2393101T3 (es)	2001-08-29	2012-12-18	Ricardo A. P. De Carvalho	Sistema implantable y sellable para la administración unidireccional de agentes terapéuticos a tejidos diana
US7749528B2 (en)	2001-08-29	2010-07-06	Ricardo Azevedo Pontes De Carvalho	Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
US20040254197A1 (en)	2001-09-28	2004-12-16	Santen Pharmaceutical Co., Ltd.	Injections for eye tissues containing drug bonded to polyethlene glycol
US20030118649A1 (en)	2001-10-04	2003-06-26	Jinming Gao	Drug delivery devices and methods
US8663687B2 (en)	2001-10-12	2014-03-04	Monosol Rx, Llc	Film compositions for delivery of actives
US20030119177A1 (en)	2001-11-15	2003-06-26	Lewis Gruber	Sample chip
GB2399753B (en)	2002-01-18	2006-04-19	Michael E Snyder	Method of making a sustained release ophthalmological device
US8364229B2 (en)	2003-07-25	2013-01-29	Dexcom, Inc.	Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
RU2322233C2 (ru)	2002-03-11	2008-04-20	Алькон, Инк.	Имплантируемая система для доставки лекарственных средств
US7074426B2 (en)	2002-03-27	2006-07-11	Frank Kochinke	Methods and drug delivery systems for the treatment of orofacial diseases
US7968569B2 (en)	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7939094B2 (en)	2002-06-19	2011-05-10	Boston Scientific Scimed, Inc.	Multiphase polymeric drug release region
ATE424187T1 (de)	2002-07-15	2009-03-15	Alcon Inc	Bioerodierbare folie zur abgabe eines ophthalmischen arzneimittels
US8425549B2 (en)	2002-07-23	2013-04-23	Reverse Medical Corporation	Systems and methods for removing obstructive matter from body lumens and treating vascular defects
US20040019325A1 (en)	2002-07-29	2004-01-29	Medrip Ltd.	Syringe Pump
US7468065B2 (en)	2002-09-18	2008-12-23	Allergan, Inc.	Apparatus for delivery of ocular implants
TWI282271B (en)	2002-09-18	2007-06-11	Allergan Inc	Apparatus for delivery of ocular implants
WO2004028477A2 (en)	2002-09-29	2004-04-08	Surmodics, Inc.	Methods for treatment and/or prevention of retinal disease
US7794437B2 (en)	2003-01-24	2010-09-14	Doheny Retina Institute	Reservoirs with subretinal cannula for subretinal drug delivery
WO2004073551A2 (en)	2003-02-18	2004-09-02	Massachusetts Eye And Ear Infirmary	Transscleral drug delivery device and related methods
US20060258000A1 (en)	2003-02-26	2006-11-16	Allen Jared W	Use of steady-state oxygen gradients to modulate animal cell functions
US20050074497A1 (en)	2003-04-09	2005-04-07	Schultz Clyde L.	Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en)	2003-04-09	2005-11-17	Directcontact Llc	Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US7094222B1 (en)	2003-04-28	2006-08-22	The United States Of America As Represented By The Secretary Of Navy	Syringe device for simultaneous infusion and withdrawal
EP1671624B1 (en)	2003-05-02	2010-08-11	SurModics, Inc.	Delivery device for a controlled drug release of an active agent into the posterior section of the eye
JP4824549B2 (ja)	2003-05-02	2011-11-30	サーモディクス，インコーポレイティド	制御放出型の生体活性物質デリバリー・デバイス
EP1635876A4 (en)	2003-06-13	2009-05-06	Becton Dickinson Co	IMPROVED INTRADERMAL ADMINISTRATION OF BIOACTIVE AGENTS
US20040260381A1 (en)	2003-06-18	2004-12-23	D-Crown Ltd	Devices and methods for forming stenting structures in situ
WO2004112653A2 (en)	2003-06-18	2004-12-29	D-Crown Ltd.	Devices and methods for delivering and forming single and multiple stenting structures in situ
US20040260380A1 (en)	2003-06-18	2004-12-23	D-Crown Ltd	Devices for delivering multiple stenting structures in situ
US8367410B2 (en)	2003-06-20	2013-02-05	Massachusetts Institute Of Technology	Application of electrical stimulation for functional tissue engineering in vitro and in vivo
EP1684669A4 (en)	2003-07-10	2008-01-02	Alcon Inc	DEVICE FOR RELEASING AN OPHTHALMIC MEDICINAL PRODUCT
FI120333B (fi)	2003-08-20	2009-09-30	Bioretec Oy	Huokoinen lääketieteellinen väline ja menetelmä sen valmistamiseksi
CA2539324A1 (en)	2003-09-18	2005-03-31	Macusight, Inc.	Transscleral delivery
US20050181018A1 (en)	2003-09-19	2005-08-18	Peyman Gholam A.	Ocular drug delivery
EP1675636A4 (en)	2003-09-24	2009-12-23	Medi Stream Pty Ltd	MEDICATION HOLDER
AU2006225241B2 (en)	2003-09-24	2008-07-17	Tianda Pharmaceuticals (Australia) Pty Limited	Medication Holder
WO2005033798A2 (en)	2003-10-03	2005-04-14	University Of Washington	Electrochemical micromanufacturing system and method
US7211272B2 (en)	2003-12-22	2007-05-01	Bausch & Lomb Incorporated	Drug delivery device
AU2005214040B2 (en)	2004-02-12	2011-03-31	Neo Vista, Inc.	Methods and apparatus for intraocular brachytherapy
US7276050B2 (en)	2004-03-02	2007-10-02	Alan Franklin	Trans-scleral drug delivery method and apparatus
WO2005091922A2 (en)	2004-03-03	2005-10-06	Becton, Dickinson And Company	Methods and devices for improving delivery of a substance to skin
US8591885B2 (en)	2004-04-30	2013-11-26	Allergan, Inc.	Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20060182783A1 (en)	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
US20050244472A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244469A1 (en)	2004-04-30	2005-11-03	Allergan, Inc.	Extended therapeutic effect ocular implant treatments
US20070059336A1 (en)	2004-04-30	2007-03-15	Allergan, Inc.	Anti-angiogenic sustained release intraocular implants and related methods
US8685435B2 (en)	2004-04-30	2014-04-01	Allergan, Inc.	Extended release biodegradable ocular implants
WO2006014484A2 (en)	2004-07-02	2006-02-09	Surmodics, Inc.	Methods and devices for the treatment of ocular conditions
US7117870B2 (en)	2004-07-26	2006-10-10	Clarity Corporation	Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
WO2006013376A2 (en) *	2004-08-04	2006-02-09	Biocompatibles Uk Limited	Drug delivery of a cox inhibitor from embolic agents
AU2005267734A1 (en)	2004-08-06	2006-02-09	Sopherion Therapeutics, Inc.	Anti-angiogenic peptides and methods of use thereof
WO2006031358A2 (en)	2004-08-13	2006-03-23	Hyperbranch Medical Technology, Inc.	Dendritic polymers, crosslinked gels, and their uses as ophthalmic sealants and lenses
WO2006023530A2 (en)	2004-08-16	2006-03-02	Massachusetts Institute Of Technology	Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
WO2006031388A2 (en)	2004-08-20	2006-03-23	Hyperbranch Medical Technology, Inc.	Dentritic polymers, crosslinked gels, and their uses in orthopedic applications
US20060052754A1 (en)	2004-09-04	2006-03-09	Fields Douglas W	Thumb trigger syringe pole
WO2006031532A2 (en)	2004-09-10	2006-03-23	Surmodics, Inc.	Methods, devices, and coatings for controlled active agent release
US20080038316A1 (en)	2004-10-01	2008-02-14	Wong Vernon G	Conveniently implantable sustained release drug compositions
EP2452670A1 (en)	2004-10-01	2012-05-16	Ramscor, Inc.	Conveniently implantable sustained release drug compositions
US20080207502A1 (en)	2004-10-14	2008-08-28	Sopherion Therapeutics, Inc.	Anti-Angiogenic Peptides and Methods of Use Thereof
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
EP1817003B1 (en)	2004-10-29	2018-02-21	The Regents of The University of California	Porous silicon microparticles for drug delivery to the eye
US20060129215A1 (en)	2004-12-09	2006-06-15	Helmus Michael N	Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
US20060154981A1 (en)	2005-01-12	2006-07-13	Alcon, Inc.	Method of reducing intraocular pressure and treating glaucoma
WO2006082588A2 (en)	2005-02-07	2006-08-10	Pharmalight Inc.	Method and device for ophthalmic administration of active pharmaceutical ingredients
US20060257450A1 (en)	2005-03-21	2006-11-16	Sreenivasu Mudumba	Drug delivery systems for treatment of diseases or conditions
US8663639B2 (en) *	2005-02-09	2014-03-04	Santen Pharmaceutical Co., Ltd.	Formulations for treating ocular diseases and conditions
US20060233858A1 (en)	2005-03-08	2006-10-19	Allergan, Inc.	Systems and methods providing targeted intraocular drug delivery
US20070077270A1 (en)	2005-03-28	2007-04-05	Clemson University	Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
EP1875560A4 (en)	2005-04-05	2011-02-09	Univ Ohio State	DIFFUSION DELIVERY SYSTEM AND METHODS OF MAKING
US20060228390A1 (en) *	2005-04-07	2006-10-12	Williams David F	Intravitreal implant
US20100168535A1 (en)	2006-04-12	2010-07-01	Mark Ries Robinson	Methods and apparatuses related to blood analyte measurement system
US20060258994A1 (en)	2005-05-12	2006-11-16	Avery Robert L	Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20070088414A1 (en)	2005-05-25	2007-04-19	Campbell Robert L	Particulate formulations for intradermal delivery of biologically active agents
TW200716140A (en)	2005-06-17	2007-05-01	Dynamis Therapeutics Inc	Treatment of inflammatory conditions
US7893040B2 (en)	2005-07-22	2011-02-22	Oculis Ehf	Cyclodextrin nanotechnology for ophthalmic drug delivery
US8663673B2 (en)	2005-07-29	2014-03-04	Surmodics, Inc.	Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility
WO2007021671A2 (en)	2005-08-10	2007-02-22	Insight Instruments, Inc.	Tool for extracting vitreous samples from an eye
US20070212397A1 (en)	2005-09-15	2007-09-13	Roth Daniel B	Pharmaceutical delivery device and method for providing ocular treatment
WO2007035621A1 (en)	2005-09-16	2007-03-29	(Osi) Eyetech, Inc.	Ophthalmic syringe
WO2007038453A2 (en)	2005-09-26	2007-04-05	Advanced Ocular Systems Limited	Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20070071756A1 (en)	2005-09-26	2007-03-29	Peyman Gholam A	Delivery of an agent to ameliorate inflammation
US20080003219A1 (en)	2005-09-26	2008-01-03	Minu, L.L.C.	Delivery of an ocular agent
US20070072933A1 (en)	2005-09-26	2007-03-29	Peyman Gholam A	Delivery of an ocular agent
US20080167600A1 (en) *	2005-09-26	2008-07-10	Peyman Gholam A	Device for delivery of an agent to the eye and other sites
TW200732347A (en)	2005-10-06	2007-09-01	Trophogen Inc	VEGF analogs and methods of use
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20090043253A1 (en)	2005-10-11	2009-02-12	Blake Podaima	Smart medical compliance method and system
BRPI0617414A2 (pt)	2005-10-14	2011-07-26	Alcon Inc	mÉtodo para tratamento de formas primÁrias e secundÁrias de glaucoma
US20080125406A1 (en)	2005-10-14	2008-05-29	Robin Alan L	Method for Treating Primary and Secondary Forms of Glaucoma
JP4721425B2 (ja)	2005-12-01	2011-07-13	キヤノン株式会社	流体移動方法および流体移動装置
CN101336315B (zh)	2005-12-07	2012-12-19	特拉维夫大学拉莫特有限公司	药物递送复合结构
US20070131610A1 (en)	2005-12-13	2007-06-14	General Electric Company	Membrane-based apparatus and associated method
US20070131611A1 (en)	2005-12-13	2007-06-14	General Electric Company	Membrane-based article and associated method
EP3338743A1 (en)	2006-01-17	2018-06-27	Novartis Ag	Drug delivery treatment device
ES2762239T3 (es)	2006-01-17	2020-05-22	Alcon Inc	Dispositivo de tratamiento del glaucoma
US20080216736A1 (en)	2006-01-19	2008-09-11	Takeda San Diego, Inc.	Microfluidic device with diffusion between adjacent lumens
US8979770B2 (en)	2006-02-24	2015-03-17	Merck Sharp & Dohme Corp.	Extraction and diagnostic fluid devices, systems and methods of use
US7625927B2 (en)	2006-02-27	2009-12-01	Alcon Research, Ltd.	Method of treating glaucoma
US20070212386A1 (en)	2006-03-08	2007-09-13	Sahajanand Medical Technologies Pvt. Ltd.	Coatings for implantable medical devices
WO2007115259A2 (en)	2006-03-31	2007-10-11	Qlt Plug Delivery, Inc.	Nasolacrimal drainage system implants for drug therapy
US20100297046A1 (en)	2006-03-31	2010-11-25	Dynamis Therapeutics, Inc.	Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
US7547300B2 (en)	2006-04-12	2009-06-16	Icu Medical, Inc.	Vial adaptor for regulating pressure
JP4889789B2 (ja)	2006-04-18	2012-03-07	チョンシャンボータイファーマシューティックインストゥルメンツカンパニーリミテッド	無菌混合薬剤注射器
US8197435B2 (en)	2006-05-02	2012-06-12	Emory University	Methods and devices for drug delivery to ocular tissue using microneedle
US7918814B2 (en)	2006-05-02	2011-04-05	Georgia Tech Research Corporation	Method for drug delivery to ocular tissue using microneedle
US7981096B2 (en)	2006-05-12	2011-07-19	David Castillejos	Optic nerve head implant and medication delivery system
US20070270750A1 (en)	2006-05-17	2007-11-22	Alcon, Inc.	Drug delivery device
US20080124372A1 (en)	2006-06-06	2008-05-29	Hossainy Syed F A	Morphology profiles for control of agent release rates from polymer matrices
JP2009542710A (ja)	2006-06-28	2009-12-03	サーモディクス，インコーポレイティド	活性剤送達用分解性及び非分解性マトリックスの併用
TW200815045A (en)	2006-06-29	2008-04-01	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008009120A2 (en)	2006-07-19	2008-01-24	Noab Biodiscoveries Inc.	Method and device to extract components contained in a fluid
US20080152694A1 (en)	2006-07-20	2008-06-26	Neurosystec Corporation	Devices, Systems and Methods for Ophthalmic Drug Delivery
WO2008016712A2 (en)	2006-08-02	2008-02-07	Inframat Corporation	Medical devices and methods of making and using
US9039761B2 (en)	2006-08-04	2015-05-26	Allergan, Inc.	Ocular implant delivery assemblies with distal caps
JP2008054521A (ja)	2006-08-29	2008-03-13	Canon Inc	細胞培養処理装置及び細胞培養処理方法
US20080057106A1 (en) *	2006-08-29	2008-03-06	Erickson Signe R	Low profile bioactive agent delivery device
US8821943B2 (en)	2006-09-12	2014-09-02	Board Of Regents Of The University Of Nebraska	Methods and compositions for targeted delivery of therapeutic agents
US20080066739A1 (en)	2006-09-20	2008-03-20	Lemahieu Edward	Methods and systems of delivering medication via inhalation
US9149750B2 (en)	2006-09-29	2015-10-06	Mott Corporation	Sinter bonded porous metallic coatings
JP5694664B2 (ja)	2006-09-29	2015-04-01	サーモディクス，インコーポレイティド	生分解性眼用インプラント及び眼の病気を治療する方法
TW200817039A (en)	2006-10-06	2008-04-16	Dynamis Therapeutics Inc	Compositions and methods for skin lightening
US9022970B2 (en)	2006-10-16	2015-05-05	Alcon Research, Ltd.	Ophthalmic injection device including dosage control device
AU2007308840C1 (en)	2006-10-25	2014-09-25	Revalesio Corporation	Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8784898B2 (en)	2006-10-25	2014-07-22	Revalesio Corporation	Methods of wound care and treatment
CA2667614A1 (en)	2006-10-25	2008-09-25	Revalesio Corporation	Method of wound care and treatment
US8784897B2 (en)	2006-10-25	2014-07-22	Revalesio Corporation	Methods of therapeutic treatment of eyes
US8609148B2 (en)	2006-10-25	2013-12-17	Revalesio Corporation	Methods of therapeutic treatment of eyes
US20080111282A1 (en)	2006-11-10	2008-05-15	Baojun Xie	Process for Making Three Dimensional Objects From Dispersions of Polymer Colloidal Particles
CA2668954C (en)	2006-11-10	2020-09-08	Glaukos Corporation	Uveoscleral shunt and methods for implanting same
US20100286791A1 (en)	2006-11-21	2010-11-11	Goldsmith David S	Integrated system for the ballistic and nonballistic infixion and retrieval of implants
US20090263346A1 (en)	2006-12-05	2009-10-22	David Taft	Systems and methods for delivery of drugs
EP2101745A4 (en)	2006-12-05	2009-12-30	Landec Corp	DISTRIBUTION OF MEDICINAL PRODUCTS
US20080154241A1 (en)	2006-12-07	2008-06-26	Burkstrand Michael J	Latent stabilization of bioactive agents releasable from implantable medical articles
US20080147021A1 (en)	2006-12-15	2008-06-19	Jani Dharmendra M	Drug delivery devices
AR063619A1 (es)	2006-12-18	2009-02-04	Alcon Res Ltd	Dispositivos y metodos para la administraicion de un farmaco oftalmico
EP2097044A4 (en)	2006-12-26	2012-10-10	Quadra Logic Tech Inc	DRUG RELIEF IMPLANTS FOR INHIBITING OPTICAL DEFECTS
DK2124856T3 (en)	2007-01-09	2019-02-11	Fovea Pharmaceuticals	DEVICE FOR INTRAOCULAR INJECTION
AU2008206953A1 (en)	2007-01-19	2008-07-24	Cinvention Ag	Porous, non-degradable implant made by powder molding
UY30883A1 (es)	2007-01-31	2008-05-31	Alcon Res	Tapones punctales y metodos de liberacion de agentes terapeuticos
GB0702864D0 (en)	2007-02-14	2007-03-28	Benoist Girard Sas	Prosthetic implant for use without bone cement
WO2008116165A2 (en)	2007-03-21	2008-09-25	Next Safety, Inc.	Methods and systems of delivering medication via inhalation
US20080249501A1 (en)	2007-04-09	2008-10-09	Medtronic Vascular, Inc.	Methods for Simultaneous Injection and Aspiration of Fluids During a Medical Procedure
US20080286338A1 (en)	2007-05-15	2008-11-20	Boston Foundation For Sight	Drug delivery system with scleral lens
US8231892B2 (en)	2007-05-24	2012-07-31	Allergan, Inc.	Biodegradable drug delivery system
US9365634B2 (en)	2007-05-29	2016-06-14	Angiochem Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
CA2688344C (en)	2007-05-29	2019-09-03	Angiochem, Inc.	Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US20090036827A1 (en)	2007-07-31	2009-02-05	Karl Cazzini	Juxtascleral Drug Delivery and Ocular Implant System
US9808557B2 (en)	2007-08-10	2017-11-07	Trustees Of Tufts College	Tubular silk compositions and methods of use thereof
NZ583678A (en) *	2007-09-07	2012-03-30	Quadra Logic Tech Inc	Silicone matrix drug cores for sustained release of therapeutic agents
BRPI0817074A2 (pt)	2007-09-07	2015-03-24	Qlt Plug Delivery Inc	Aparelho, método para tratar uma desordem ocular, dispositivo de detecção e sistema de detecção
US20090105749A1 (en)	2007-09-07	2009-04-23	Qlt Plug Delivery, Inc. - Qpdi	Insertion and extraction tools for lacrimal implants
US8308755B2 (en)	2007-09-24	2012-11-13	Ethicon Endo-Surgery, Inc.	Elliptical retractor
US20090081272A1 (en)	2007-09-24	2009-03-26	John Clarke	Medical devices having a metal particulate composition for controlled diffusion
US8974809B2 (en) *	2007-09-24	2015-03-10	Boston Scientific Scimed, Inc.	Medical devices having a filter insert for controlled diffusion
US20090214601A1 (en)	2007-09-28	2009-08-27	Chappa Ralph A	Porous Drug Delivery Devices and Related Methods
RU2475282C2 (ru)	2007-10-05	2013-02-20	Тико Хелскеа Груп Лп	Герметизирующий фиксатор для использования при хирургических операциях
US20100100043A1 (en)	2007-10-05	2010-04-22	Racenet Danyel J	Flexible Access Device For Use In Surgical Procedure
US9523090B2 (en)	2007-10-25	2016-12-20	Revalesio Corporation	Compositions and methods for treating inflammation
US20090263495A1 (en)	2007-10-25	2009-10-22	Revalesio Corporation	Bacteriostatic or bacteriocidal compositions and methods
WO2009055620A1 (en)	2007-10-25	2009-04-30	Revalesio Corporation	Bacteriostatic or bacteriocidal compositions and methods
US20100009008A1 (en)	2007-10-25	2010-01-14	Revalesio Corporation	Bacteriostatic or bacteriocidal compositions and methods
US20100303918A1 (en)	2007-10-25	2010-12-02	Revalesio Corporation	Compositions and methods for treating asthma and other lung disorders
US20090227018A1 (en)	2007-10-25	2009-09-10	Revalesio Corporation	Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100303917A1 (en)	2007-10-25	2010-12-02	Revalesio Corporation	Compositions and methods for treating cystic fibrosis
WO2010062628A1 (en)	2008-10-27	2010-06-03	Revalesio Corporation	Compositions and methods for treating asthma and other lung disorders
US20100310665A1 (en)	2007-10-25	2010-12-09	Revalesio Corporation	Bacteriostatic or bacteriocidal compositions and methods
US20100004189A1 (en)	2007-10-25	2010-01-07	Revalesio Corporation	Compositions and methods for treating cystic fibrosis
US10125359B2 (en)	2007-10-25	2018-11-13	Revalesio Corporation	Compositions and methods for treating inflammation
US20100008997A1 (en)	2007-10-25	2010-01-14	Revalesio Corporation	Compositions and methods for treating asthma and other lung disorders
CA2703000C (en)	2007-11-05	2013-08-06	Bausch & Lomb Incorporated	Water-immiscible materials as vehicles for drug delivery
US8114883B2 (en)	2007-12-04	2012-02-14	Landec Corporation	Polymer formulations for delivery of bioactive materials
EP2666510B1 (en)	2007-12-20	2017-10-18	University Of Southern California	Apparatus for controlled delivery of therapeutic agents
US8414646B2 (en)	2007-12-27	2013-04-09	Forsight Labs, Llc	Intraocular, accommodating lens and methods of use
PL2240220T3 (pl)	2008-01-03	2016-09-30		Wszczepialne urządzenia do podawania leków i aparaty do napełniania urządzeń
US20100305514A1 (en)	2008-01-10	2010-12-02	Bausch & Lomb Incorporated	Intravitreal injection system having coaxial cannulae and use thereof
WO2009094466A2 (en)	2008-01-22	2009-07-30	University Of Florida Research Foundation, Inc.	Contact lenses for extended release of bioactive agents containing diffusion attenuators
EP2257250A2 (en)	2008-01-29	2010-12-08	Gilbert H. Kliman	Drug delivery devices, kits and methods therefor
US8201752B2 (en)	2008-03-10	2012-06-19	Vapore, Inc.	Low energy vaporization of liquids: apparatus and methods
TNSN08110A1 (en)	2008-03-11	2009-07-14	Rekik Raouf Dr	Drug delivery to the anterior and posterior segment of the eye from drops
US20090240208A1 (en) *	2008-03-19	2009-09-24	Warsaw Orthopedic, Inc.	Microparticle delivery syringe and needle for placing particle suspensions and removing vehicle fluid
WO2009117112A2 (en)	2008-03-21	2009-09-24	Novartis Ag	Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents
KR101771629B1 (ko)	2008-03-31	2017-08-25	닛토덴코 가부시키가이샤	침투제 전달 시스템 및 그의 사용방법
DK2285439T3 (en)	2008-04-04	2014-03-24	Nektar Therapeutics	Aerosoliseringsanorning
US8801665B2 (en)	2008-04-10	2014-08-12	Henry Ford Health System	Apparatus and method for controlled depth of injection into myocardial tissue
WO2009128932A1 (en)	2008-04-15	2009-10-22	Sarcode Corporation	Delivery of lfa-1 antagonists to the gastrointestinal system
US9132088B2 (en)	2008-04-30	2015-09-15	Mati Therapeutics Inc.	Composite lacrimal insert and related methods
US8980325B2 (en)	2008-05-01	2015-03-17	Revalesio Corporation	Compositions and methods for treating digestive disorders
EP2320972B1 (en)	2008-05-08	2020-07-01	MiniPumps, LLC	Implantable drug-delivery devices
KR20110017365A (ko)	2008-05-30	2011-02-21	페어필드 클리니컬 트라이얼즈 엘엘씨	피부 염증 및 변색을 위한 방법 및 조성물
US10517839B2 (en)	2008-06-09	2019-12-31	Cornell University	Mast cell inhibition in diseases of the retina and vitreous
CA2769307C (en)	2008-07-11	2017-12-12	Intellicyt Corporation	Multi-sample particle analyzer system and method for high throughput screening
US8821870B2 (en)	2008-07-18	2014-09-02	Allergan, Inc.	Method for treating atrophic age related macular degeneration
AU2009274127A1 (en)	2008-07-21	2010-01-28	Arstasis, Inc.	Devices, methods, and kits for forming tracts in tissue
US20100023033A1 (en)	2008-07-25	2010-01-28	Medtronic Vescular, Inc.	Hydrodynamic Thrombectomy Catheter
US20100022943A1 (en)	2008-07-25	2010-01-28	Medtronic Vascular, Inc.	Hydrodynamic Thrombectomy Catheter
WO2010021993A1 (en)	2008-08-19	2010-02-25	Cytori Therapeutics, Inc.	Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US8221353B2 (en)	2008-10-21	2012-07-17	KMG Pharma, Inc	Intravitreal injection device and system
US7678078B1 (en)	2008-10-21	2010-03-16	KMG Pharma LLC	Intravitreal injection device, system and method
EP2367527A2 (en) *	2008-11-26	2011-09-28	SurModics, Inc.	Implantable ocular drug delivery device and methods
DE102008054431B3 (de)	2008-12-09	2010-06-17	Pari Pharma Gmbh	Aerosoltherapievorrichtung
US20100158980A1 (en)	2008-12-18	2010-06-24	Casey Kopczynski	Drug delivery devices for delivery of therapeutic agents
TW201026300A (en)	2009-01-02	2010-07-16	Alcon Res Ltd	In-situ refillable ophthalmic implant
US8545554B2 (en)	2009-01-16	2013-10-01	Allergan, Inc.	Intraocular injector
US8623395B2 (en)	2010-01-29	2014-01-07	Forsight Vision4, Inc.	Implantable therapeutic device
EP2391419B1 (en)	2009-01-29	2019-06-12	ForSight Vision4, Inc.	Posterior segment drug delivery
WO2010093945A2 (en)	2009-02-13	2010-08-19	Glaukos Corporation	Uveoscleral drug delivery implant and methods for implanting the same
ES2728225T3 (es)	2009-02-20	2019-10-23	2 Bbb Medicines B V	Sistema de administración de fármacos a base de glutatión
WO2010101989A1 (en)	2009-03-03	2010-09-10	Alcon Research, Ltd.	PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8815292B2 (en)	2009-04-27	2014-08-26	Revalesio Corporation	Compositions and methods for treating insulin resistance and diabetes mellitus
WO2010125416A1 (en)	2009-04-27	2010-11-04	Raouf Rekik	Drug delivery to the anterior and posterior segments of the eye
EP2424507A4 (en)	2009-04-27	2012-10-24	Revalesio Corp	COMPOSITIONS AND METHODS FOR THE TREATMENT OF INSULIN AND DIABETES RESISTANCE
WO2010132835A1 (en)	2009-05-15	2010-11-18	Arstasis, Inc.	Devices, methods and kits for forming tracts in tissue
CA3186189A1 (en)	2009-05-18	2010-11-25	Dose Medical Corporation	Drug eluting ocular implant
CN102596097B (zh)	2009-06-03	2015-05-20	弗赛特实验室有限责任公司	一种眼插入件
US9005649B2 (en)	2009-07-14	2015-04-14	Board Of Regents, The University Of Texas System	Methods for making controlled delivery devices having zero order kinetics
US20110033933A1 (en)	2009-07-15	2011-02-10	Morteza Gharib	Method applying hemodynamic forcing and klf2 to initiate the growth and development of cardiac valves
AU2010282282A1 (en)	2009-08-14	2012-03-01	Genentech, Inc.	Biological markers for monitoring patient response to VEGF antagonists
WO2011028850A1 (en)	2009-09-01	2011-03-10	Northwestern University	Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
EP2480270A4 (en)	2009-09-21	2015-07-08	Harvard Apparatus Regenerative Technology Inc	METHODS AND APPARATUSES FOR INTRODUCING CELLS INTO A TISSUE SITE
CA2785468A1 (en)	2009-12-23	2011-06-30	Psivida Us, Inc.	Sustained release delivery devices
US8821474B2 (en)	2010-02-22	2014-09-02	Microsert Ltd.	Slow release liquid drug delivery device
US20110301555A1 (en) *	2010-06-03	2011-12-08	Gonzalez-Zugasti Javier P	Porous matrix drug core for lacrimal insert device
ES2894940T3 (es)	2010-08-05	2022-02-16	Forsight Vision4 Inc	Aparato para tratar un ojo
WO2012019047A2 (en)	2010-08-05	2012-02-09	Forsight Vision4, Inc.	Subconjunctival implant for posterior segment drug delivery
EP2600876B1 (en)	2010-08-05	2015-04-29	Forsight Vision4, Inc.	Combined drug delivery methods and apparatus
CN103209733B (zh)	2010-08-05	2015-12-16	弗赛特影像4股份有限公司	用于药物输送的注入器装置和方法
US20140033800A1 (en)	2010-11-11	2014-02-06	Forsight Vision4, Inc.	Methods and apparatus to determine diffusion properties of porous structures for drug delivery
CA2818612C (en)	2010-11-19	2020-12-29	Forsight Vision4, Inc.	Therapeutic agent formulations for implanted devices
EP4249059A3 (en)	2011-06-28	2023-11-29	ForSight Vision4, Inc.	An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en)	2011-08-05	2015-08-12	Forsight Vision4 Inc	SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
US9883968B2 (en)	2011-09-16	2018-02-06	Forsight Vision4, Inc.	Fluid exchange apparatus and methods
WO2013116061A1 (en)	2012-02-03	2013-08-08	Forsight Vision4, Inc.	Insertion and removal methods and apparatus for therapeutic devices

2011
- 2011-08-05 EP EP20110815389 patent/EP2600876B1/en active Active
- 2011-08-05 US US13/814,466 patent/US10617557B2/en active Active
- 2011-08-05 CN CN201180048624.5A patent/CN103153316B/zh not_active Expired - Fee Related
- 2011-08-05 JP JP2013523372A patent/JP6111194B2/ja active Active
- 2011-08-05 WO PCT/US2011/046817 patent/WO2012019139A1/en active Application Filing
- 2011-08-05 CA CA2807537A patent/CA2807537C/en not_active Expired - Fee Related
- 2011-08-05 AU AU2011285548A patent/AU2011285548B2/en not_active Ceased
2020
- 2020-03-04 US US16/808,784 patent/US11679027B2/en active Active

Also Published As

Publication number	Publication date
CN103153316A (zh)	2013-06-12
US20130274691A1 (en)	2013-10-17
AU2011285548A1 (en)	2013-03-07
CN103153316B (zh)	2015-08-19
CA2807537A1 (en)	2012-02-09
EP2600876A1 (en)	2013-06-12
CA2807537C (en)	2018-09-18
US11679027B2 (en)	2023-06-20
EP2600876B1 (en)	2015-04-29
JP2013538082A (ja)	2013-10-10
AU2011285548B2 (en)	2014-02-06
US20200405537A1 (en)	2020-12-31
WO2012019139A9 (en)	2013-03-28
US10617557B2 (en)	2020-04-14
WO2012019139A1 (en)	2012-02-09
EP2600876A4 (en)	2014-01-15

Publication	Publication Date	Title
JP6111194B2 (ja)	2017-04-05	組み合わせ薬物送達方法および装置
US20230338282A1 (en)	2023-10-26	Posterior segment drug delivery
AU2016202327B2 (en)	2017-11-16	Implantable therapeutic device
AU2011285637B2 (en)	2014-10-30	Subconjunctival implant for posterior segment drug delivery
US20150297402A1 (en)	2015-10-22	Implantable Therapeutic Device
JP6063382B2 (ja)	2017-01-18	治療薬を眼の埋め込み体へと注入するためのシステム
EP2739252A1 (en)	2014-06-11	Small molecule delivery with implantable therapeutic device
AU2014202463B2 (en)	2015-09-17	Combined drug delivery methods and apparatus

Legal Events

Date	Code	Title	Description
2014-08-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140805
2014-08-06	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140805
2015-06-18	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150617
2015-06-30	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150630
2015-09-16	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150916
2015-11-02	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151102
2015-11-30	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151130
2016-01-04	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160104
2016-06-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160606
2016-09-05	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160905
2016-10-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161020
2017-02-14	TRDD	Decision of grant or rejection written
2017-02-20	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170220
2017-03-16	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170313
2017-03-17	R150	Certificate of patent or registration of utility model	Ref document number: 6111194 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2020-02-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-03-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-02-25	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-02-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-02-29	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250